Literature DB >> 9440625

Activation of tumor necrosis factor-alpha system in chronic hepatitis C virus infection.

D R Nelson1, H L Lim, C G Marousis, J W Fang, G L Davis, L Shen, M S Urdea, J A Kolberg, J Y Lau.   

Abstract

Tumor necrosis factor-alpha (TNF-alpha) plays a central role in the host's immunomodulatory response to infective agents. To evaluate the TNF-alpha system in patients with chronic hepatitis C virus (HCV) infection, plasma, serum, and peripheral blood mononuclear cells (PBMC) were prospectively collected from 53 patients and 33 healthy control subjects. Circulating TNF-alpha and TNF receptors were assayed by their respective enzyme immunoassays. In addition, TNF-alpha mRNA was quantitated in PBMC using a branched DNA assay, and production of TNF-alpha by PBMC with and without lipopolysaccharide was also assessed. Patients with chronic HCV infection had a higher level of circulating TNF-alpha compared to healthy control subjects (9.62 +/- 6.01 vs 3.66 +/- 1.23 pg/ml, P < 0.001). They also had higher circulating levels of TNF receptors compared to control (CD120a: 3323 +/- 1267, pg/ml, N = 49 vs 1855 +/- 422 pg/ml, N = 33, P < 0.001; CD120b: 1290 +/- 650 pg/ml, N = 51, vs 863 +/- 207 pg/ml, N = 33, P < 0.001). Plasma TNF-alpha level correlated with circulating CD120a (r = 0.52, N = 49, P < 0.001) and weakly with CD120b (r = 0.32, N = 51, P = 0.02). Plasma TNF-alpha also correlated with markers of hepatocellular injury, including ALT (r = 0.34, N = 53, P = 0.01) and alpha-GST (r = 0.31, N = 43, P = 0.042), but not with serum HCV RNA levels. There was no difference in the TNF-alpha mRNA levels in PBMC between patients with chronic HCV infection (1.4 +/- 1.9 units/10[6] cells, N = 8) and healthy control subjects (2.1 +/- 1.4 units/10[6] cells, N = 8, P = NS). There was also no difference in the spontaneous production of TNF-alpha by PBMC (1 x 10[6] cells/ml) between patients with chronic HCV infection (14.2 +/- 36.5 pg/ml, N = 11) and healthy subjects (11.9 +/- 14.0 pg/ml, N = 14, P = NS). However, patients with chronic HCV infection produced more TNF-alpha upon stimulation with lipopolysaccharide compared to healthy control subjects (1278 +/- 693 pg/ml, N = 11, vs 629 +/- 689 pg/ml, N = 14, P < 0.05). These data indicate that the TNF-alpha system is activated in patients with chronic HCV infection.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9440625     DOI: 10.1023/a:1018804426724

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  28 in total

1.  The role of hepatitis C virus-specific cytotoxic T lymphocytes in chronic hepatitis C.

Authors:  D R Nelson; C G Marousis; G L Davis; C M Rice; J Wong; M Houghton; J Y Lau
Journal:  J Immunol       Date:  1997-02-01       Impact factor: 5.422

2.  Branched DNA amplification multimers for the sensitive, direct detection of human hepatitis viruses.

Authors:  M S Urdea; T Horn; T J Fultz; M Anderson; J A Running; S Hamren; D Ahle; C A Chang
Journal:  Nucleic Acids Symp Ser       Date:  1991

3.  Implications of variations of "conserved" regions of hepatitis C virus genome.

Authors:  J Y Lau; P Simmonds; M S Urdea
Journal:  Lancet       Date:  1995-08-12       Impact factor: 79.321

4.  Pitfalls in measuring cytokines.

Authors:  S Kapadia; G Torre-Amione; D L Mann
Journal:  Ann Intern Med       Date:  1994-07-15       Impact factor: 25.391

5.  Hepatitis C virus (HCV)-specific cytotoxic T lymphocytes recognize epitopes in the core and envelope proteins of HCV.

Authors:  M J Koziel; D Dudley; N Afdhal; Q L Choo; M Houghton; R Ralston; B D Walker
Journal:  J Virol       Date:  1993-12       Impact factor: 5.103

6.  Apoptosis in cultured rat hepatocytes: the effects of tumour necrosis factor alpha and interferon gamma.

Authors:  T Shinagawa; K Yoshioka; S Kakumu; T Wakita; T Ishikawa; Y Itoh; M Takayanagi
Journal:  J Pathol       Date:  1991-11       Impact factor: 7.996

7.  Hepatic expression of type A and type B receptors for tumor necrosis factor.

Authors:  R Volpes; J J van den Oord; R De Vos; V J Desmet
Journal:  J Hepatol       Date:  1992-03       Impact factor: 25.083

8.  Typing of hepatitis C virus isolates and characterization of new subtypes using a line probe assay.

Authors:  L Stuyver; R Rossau; A Wyseur; M Duhamel; B Vanderborght; H Van Heuverswyn; G Maertens
Journal:  J Gen Virol       Date:  1993-06       Impact factor: 3.891

9.  Infection of peripheral blood mononuclear cells by herpes simplex and Epstein-Barr viruses. Differential induction of interleukin 6 and tumor necrosis factor-alpha.

Authors:  J Gosselin; L Flamand; M D'Addario; J Hiscott; J Menezes
Journal:  J Clin Invest       Date:  1992-06       Impact factor: 14.808

10.  Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis.

Authors:  R G Knodell; K G Ishak; W C Black; T S Chen; R Craig; N Kaplowitz; T W Kiernan; J Wollman
Journal:  Hepatology       Date:  1981 Sep-Oct       Impact factor: 17.425

View more
  53 in total

1.  Kinetics of soluble tumour necrosis factor (TNF)-alpha receptors and cytokines in the early phase of treatment for chronic hepatitis C: comparison between interferon (IFN)-alpha alone, IFN-alpha plus amantadine or plus ribavirin.

Authors:  F Torre; S Rossol; N Pelli; M Basso; A Delfino; A Picciotto
Journal:  Clin Exp Immunol       Date:  2004-06       Impact factor: 4.330

2.  Hepatitis C virus treatment complicated by rheumatoid arthritis.

Authors:  Meredith Borman; Mark G Swain
Journal:  Gastroenterol Hepatol (N Y)       Date:  2011-11

3.  Etanercept treatment to enable successful hepatitis C virus clearance in a patient with rheumatoid arthritis.

Authors:  Alison B Jazwinski; Janet Jezsik; Stacy P Ardoin; Rex M McCallum; Hans L Tillmann
Journal:  Gastroenterol Hepatol (N Y)       Date:  2011-11

4.  Higher CD163 levels are associated with insulin resistance in hepatitis C virus-infected and HIV-infected adults.

Authors:  Michael Reid; Yifei Ma; Rebecca Scherzer; Jennifer C Price; Audrey L French; Michael W Plankey; Carl Grunfeld; Phyllis C Tien
Journal:  AIDS       Date:  2017-01-28       Impact factor: 4.177

5.  Effects of HCV treatment on cytokine expression during HCV/HIV coinfection.

Authors:  Jason T Blackard; Minhee Kang; Kenneth E Sherman; Margaret James Koziel; Marion G Peters; Raymond T Chung
Journal:  J Interferon Cytokine Res       Date:  2006-11       Impact factor: 2.607

6.  Chronic pain and hepatitis C virus infection in opioid dependent injection drug users.

Authors:  Judith I Tsui; Debra S Herman; Malyna Kettavong; Bradley J Anderson; Michael D Stein
Journal:  J Addict Dis       Date:  2011-04

Review 7.  Hepatitis C virus and metabolic disorder interactions towards liver damage and atherosclerosis.

Authors:  Umberto Vespasiani-Gentilucci; Paolo Gallo; Antonio De Vincentis; Giovanni Galati; Antonio Picardi
Journal:  World J Gastroenterol       Date:  2014-03-21       Impact factor: 5.742

8.  Viral factors associated with cytokine expression during HCV/HIV co-infection.

Authors:  Jason T Blackard; Minhee Kang; J Benjamin St Clair; Wenyu Lin; Yoshitaka Kamegaya; Kenneth E Sherman; Margaret James Koziel; Marion G Peters; Janet Andersen; Raymond T Chung
Journal:  J Interferon Cytokine Res       Date:  2007-04       Impact factor: 2.607

Review 9.  Pathogenic interactions between alcohol and hepatitis C.

Authors:  Gyongyi Szabo
Journal:  Curr Gastroenterol Rep       Date:  2003-02

10.  Fatigue is associated with high circulating leptin levels in chronic hepatitis C.

Authors:  T Piche; E Gelsi; S M Schneider; X Hébuterne; J Giudicelli; B Ferrua; C Laffont; S Benzaken; P Hastier; M L Montoya; F Longo; P Rampal; A Tran
Journal:  Gut       Date:  2002-09       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.